Immunotherapy

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.

What is Immunotherapy?

Immunotherapy is a treatment that is designed to harness the ability of the body’s immune system to combat infection or disease.

Activation Immunotherapies

Immunotherapy and Helminthic Therapy

Suppression Immunotherapies

Immunotherapy: Past, Present and Future

Adoptive T Cell Therapy Methodology

Adoptive T Cell Therapy Applications

Immunotherapy: The Future of Lung Cancer Treatment?

Neoantigens' Role in Immunotherapy

Latest Immunotherapy News and Research

Gut bacteria Ruminococcus gnavus can enhance the effects of cancer immunotherapy

Roughly one in five cancer patients benefits from immunotherapy – a treatment that harnesses the immune system to fight cancer.

17 May 2024

Immune checkpoint protein VISTA can directly turn off T-cells during immunotherapy, study finds

A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment.

17 May 2024

Liquid biopsy biomarker predicts melanoma therapy response

If black skin cancer (melanoma) spreads, there are various therapies that can be used. However, there is still insufficient research into who responds to which therapy and whether resistance may develop over time.

16 May 2024

Perioperative immunotherapy improves event-free survival in patients with resectable NSCLC

Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer(NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.

16 May 2024

New PET imaging biomarker Gal-1 predicts tumor responses to immunotherapy

The protein galectin-1 (Gal-1) has been identified as a new PET imaging biomarker for immune checkpoint blockade (ICB) therapy, allowing physicians to predict the tumor responses before beginning treatment.

15 May 2024

What is the ‘immune self,’ and how can this concept benefit immunological research?

A perspective review discusses the concept of the 'immune self' and how adaptive immune responses are influenced by self-similarity. The study emphasizes advances and challenges in defining self-similarity and its impact on immunological research.

13 May 2024

Experimental gene therapy shows promise for treating herpes infections

Researchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection and suppressed how much virus can be released from an infected individual, which suggests that the therapy would also reduce the spread of the virus.

13 May 2024

Research unlocks the role of macrophages in cancer relapse

Researchers from the Cancer Science Institute of Singapore at the National University of Singapore (NUS), have achieved breakthroughs in understanding relapse after chemotherapy for a type of cancer known as diffuse large B-cell lymphoma (DLBCL).

13 May 2024

Expanding treatment horizons for hypermutated urothelial carcinomas beyond immunotherapy

A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, "Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy."

10 May 2024

Breakthrough research offers promise for developing new immune therapies for cancer

Scientists from Trinity College Dublin have made an important breakthrough that offers promise for developing new immune therapies for cancer.

9 May 2024

Combination immunotherapy treatment enhances immune response for people with malignant gliomas

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an aggressive type of brain tumor that is fast growing and difficult to treat.

9 May 2024

Enhancing the ability of natural killer cells to combat hematologic malignancies

A new study reveals a groundbreaking approach to immunotherapy, demonstrating that blocking the interaction between the CD300A receptor and phosphatidylserine (PS) significantly enhances the ability of human natural killer (NK) cells to lyse hematologic malignancies (HMs).

9 May 2024

Researchers enhance CAR-T cells to target solid tumors

Researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) have shown that a breakthrough therapy for treating blood cancers can be adapted to treat solid tumors-;an advance that could transform cancer treatment.

8 May 2024

AI-driven model identifies potent cancer-killing immune cells for personalized immunotherapy

Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies.

7 May 2024

Durable lymph-node expansion improves vaccine responses against tumors

Each one of us has around 600 lymph nodes (LNs) – small, bean-shaped organs that house various types of blood cells and filter lymph fluid – scattered throughout our bodies.

6 May 2024

NK cells' role in cancer therapy resistance unveiled

Activated T cells that carry a certain marker protein on their surface are controlled by natural killer (NK) cells, another cell type of the immune system.

3 May 2024

Unlocking glioblastoma's immune suppression mechanism

The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma -; a serious and often fatal brain cancer -; suppresses the immune system so that the tumor can grow unimpeded by the body's defenses.

3 May 2024